To Our New Jersey Life Sciences Community:
Welcome to another edition of The Weekender.
Congratulations New Jersey on being 100 percent!!
Following the success touted at the Annual Dinner Meeting and Innovation Celebration earlier this month, companies with a footprint in New Jersey are responsible for 100 percent of the innovator drugs (NME/BLA) approved by the FDA to date in 2015. Congratulations to these companies and please keep the innovation coming! Because Patients Can’t Wait!
Actavis – AVYCAZ
Daiichi Sankyo – Savaysa
Eisai – Lenvima
Novartis – Cosentyx
Novartis – Farydak
NPS Pharma – Natpara
Pfizer – Ibrance
Sanofi – Toujeo
Thanks to New Jersey Congressman Leonard Lance for his continuing support of the life sciences industry. Earlier this week, Congressman Lance and Congresswoman Anna Eshoo of California re-introduced the FDA Safety Over Sequestration Act, or FDA SOS Act, which would exempt privately paid user fees paid to the FDA from any future budget sequestration operations.
With Rare Disease Day coming up tomorrow, BioNJ is proud to support and bring awareness to this important day. BioNJ co-sponsored an EDSers United event held at Robert Wood Johnson hospital in Hamilton. We are also happy to support the New Jersey Rare Disease Alliance and NORD in an awareness-building event at the State House in Trenton on March 16.
Meanwhile, in Trenton, Governor Chris Christie introduced his proposed budget for Fiscal Year 2016. Of interest to the life sciences industry, the budget recommends the adoption of legislation that would permit the voluntary conversion of outstanding Business Employment Program (BEIP) grant commitments into refundable tax credits. BioNJ as part of its advocacy initiatives, will report more on the budget as it proceeds through the State legislature.
Contravir CEO James Contravir (left) announced that his company has joined the NASDAQ earlier this week. The NASDAQ Stock Market LLC has approved the Company’s application to have its common stock listed on the NASDAQ Capital Market. Effective at the opening of trading on February 27, 2015, the Company’s common stock will trade on the NASDAQ Capital Market under its existing symbol “CTRV.” Congratulations to James and his team!
Finally, if you hadn’t seen the news earlier this week, the BioNJ Purchasing Consortium has a new look and an array of offerings. We’re excited to announce a multitude of options for Members to take advantage of, including suppliers in research and development, professional services and marketing services. Visit the Purchasing Consortium today to find out how to take advantage of the savings.
Click here to read this week’s Weekender.